Nuzenio

Gilead Sciences Raises

Gilead Sciences Raises news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 7 publisher sources 100/100 entity strength

Latest news

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength - Yahoo Finance SingaporeYahoo Finance Singapore · Fri, 07 Aug 2026 14:00:00 GMTCzech National Bank Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeatMarketBeat · Fri, 07 Aug 2026 11:49:10 GMTGILEAD : RBC RAISES TARGET PRICE TO $123 FROM $120 - MoomooMoomoo · Thu, 06 Aug 2026 19:33:38 GMTGilead Sciences (GILD) Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation - simplywall.stsimplywall.st · Wed, 05 Aug 2026 15:41:47 GMTGilead raises full-year guidance on 8% Q2 sales growth, eyes three near-term regulatory approvals - AllSciAllSci · Wed, 05 Aug 2026 14:17:35 GMTGilead lifts sales outlook on strong Q2 HIV growth despite acquisition-related loss - The Pharma LetterThe Pharma Letter · Wed, 05 Aug 2026 13:02:31 GMTGilead Raised HIV Guidance on Its Q2 Earnings Call. Here’s What That Means for GILD Stock. - TIKR.comTIKR.com · Wed, 05 Aug 2026 10:39:48 GMT

Timeline

Fri, 07 Aug 2026 14:00:00 GMTGILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength - Yahoo Finance Singapore
Fri, 07 Aug 2026 11:49:10 GMTCzech National Bank Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Thu, 06 Aug 2026 19:33:38 GMTGILEAD : RBC RAISES TARGET PRICE TO $123 FROM $120 - Moomoo
Wed, 05 Aug 2026 15:41:47 GMTGilead Sciences (GILD) Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation - simplywall.st
Wed, 05 Aug 2026 14:17:35 GMTGilead raises full-year guidance on 8% Q2 sales growth, eyes three near-term regulatory approvals - AllSci
Wed, 05 Aug 2026 13:02:31 GMTGilead lifts sales outlook on strong Q2 HIV growth despite acquisition-related loss - The Pharma Letter

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Gilead Sciences Raises.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.